Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.

Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.

Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.

PMID:
30475942
2.

Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer.

Rouach V, Goldshtein I, Wolf I, Catane R, Chodick G, Iton A, Stern N, Cohen D.

J Bone Oncol. 2018 Aug 8;12:91-95. doi: 10.1016/j.jbo.2018.07.011. eCollection 2018 Sep.

3.

Cancer risk among Holocaust survivors in Israel-A nationwide study.

Sadetzki S, Chetrit A, Freedman LS, Hakak N, Barchana M, Catane R, Shani M.

Cancer. 2017 Sep 1;123(17):3335-3345. doi: 10.1002/cncr.30783. Epub 2017 Jul 10.

4.

Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.

Tahover E, Segal A, Isacson R, Rosengarten O, Grenader T, Gips M, Cherny N, Heching NI, Mesika L, Catane R, Gabizon A.

Anticancer Drugs. 2017 Aug;28(7):787-794. doi: 10.1097/CAD.0000000000000514.

PMID:
28562379
5.

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.

Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, Shabtai M, Zippel D, Gutman M, Golan T, Yosepovich A, Catane R, Modiano T, Kaufman B.

Breast Cancer Res Treat. 2016 May;157(1):157-65. doi: 10.1007/s10549-016-3800-5. Epub 2016 Apr 25.

PMID:
27113739
6.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

7.

Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.

Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, Kuchuk I, Hourvitz A, Levron J, Mozer-Mendel M, Brengauz M, Biderman H, Manela D, Catane R, Dor J, Orvieto R, Kaufman B.

Fertil Steril. 2014 Aug;102(2):488-495.e3. doi: 10.1016/j.fertnstert.2014.05.017. Epub 2014 Jun 14.

PMID:
24934489
8.

Parametric diffusion tensor imaging of the breast.

Eyal E, Shapiro-Feinberg M, Furman-Haran E, Grobgeld D, Golan T, Itzchak Y, Catane R, Papa M, Degani H.

Invest Radiol. 2012 May;47(5):284-91. doi: 10.1097/RLI.0b013e3182438e5d.

PMID:
22472798
9.

Association between very young age and adverse characteristics of breast cancer at presentation amongst Israeli women.

Paluch-Shimon S, Wolf I, Sadetzki S, Gluck I, Oberman B, Papa MZ, Catane R, Kaufman B.

Am J Clin Oncol. 2011 Jun;34(3):219-22. doi: 10.1097/COC.0b013e3181d6b500.

PMID:
20523208
10.

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J.

Clin Cancer Res. 2010 May 1;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041. Epub 2010 Apr 20.

11.

Immunosuppressive treatments reduce long-term immunity to smallpox among patients with breast cancer.

Wiser I, Orr N, Kaufman B, Segev S, Smetana Z, Bialik A, Epstein N, Mendelson E, Catane R, Cohen D.

J Infect Dis. 2010 May 15;201(10):1527-34. doi: 10.1086/651950.

PMID:
20388035
12.

Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.

Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.

Oncogene. 2010 Jan 7;29(1):26-33. doi: 10.1038/onc.2009.301. Epub 2009 Oct 5.

PMID:
19802015
13.

European Society for Medical Oncology (ESMO) Program for the integration of oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program.

Cherny N, Catane R, Schrijvers D, Kloke M, Strasser F.

Ann Oncol. 2010 Feb;21(2):362-9. doi: 10.1093/annonc/mdp318. Epub 2009 Aug 4.

PMID:
19654197
14.

Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.

Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B.

Am J Clin Oncol. 2009 Oct;32(5):504-8. doi: 10.1097/COC.0b013e3181967d72.

PMID:
19564785
15.

Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients.

Gluck I, Simon AJ, Catane R, Pfeffer R, Schachter J, Rechavi G, Bar J.

Melanoma Res. 2009 Aug;19(4):199-202. doi: 10.1097/CMR.0b013e32832ccd27.

PMID:
19455066
16.

Serum tumor markers in oncology.

Urban D, Catane R.

Isr Med Assoc J. 2009 Feb;11(2):103-4. No abstract available.

17.

The management of cancer pain in the elderly.

Urban D, Cherny N, Catane R.

Crit Rev Oncol Hematol. 2010 Feb;73(2):176-83. doi: 10.1016/j.critrevonc.2009.03.008. Epub 2009 Apr 15. Review.

PMID:
19372049
18.

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi A, Shalmon B, Hardan I, Catane R, Segal E, Markel G, Apter S, Nun AB, Kuchuk I, Shimoni A, Nagler A, Schachter J.

J Immunother. 2009 May;32(4):415-23. doi: 10.1097/CJI.0b013e31819c8bda.

PMID:
19342963
19.

Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.

Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, Sulkes A, Gutman H, Catane R, Schachter J.

Oncol Rep. 2008 Dec;20(6):1533-8.

PMID:
19020738
20.

Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study.

Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, Chander G, Hengst S, Pfeffer R, Chechick A, Hanannel A, Dogadkin O, Catane R.

Ann Surg Oncol. 2009 Jan;16(1):140-6. doi: 10.1245/s10434-008-0011-2. Epub 2008 Nov 11.

PMID:
19002530
21.

Adjuvant chemotherapy and whole abdominal irradiation for gastric carcinoma.

Kundel Y, Levitt ML, Oberman B, Sadezki S, Tichler T, Symon Z, Catane R, Pfeffer R, Brenner B.

Tumori. 2008 Jul-Aug;94(4):469-73.

PMID:
18822680
22.

[Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer].

Mendlovic S, Symon Z, Kundel Y, Rabin T, Catane R, Pfeffer R.

Harefuah. 2008 May;147(5):384-7, 480. Hebrew.

PMID:
18770957
23.

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.

Paluch-Shimon S, Wolf I, Goldberg H, Evron E, Papa MZ, Shabtai M, Barsuk D, Yosepovich A, Modiano T, Catane R, Kaufman B.

Acta Oncol. 2008;47(8):1564-9. doi: 10.1080/02841860802060844.

PMID:
18607846
24.

Magnetic resonance guided focused ultrasound surgery. Ablation of soft tissue at bone-muscle interface in a porcine model.

Kopelman D, Inbar Y, Hanannel A, Pfeffer RM, Dogadkin O, Freundlich D, Liberman B, Catane R.

Eur J Clin Invest. 2008 Apr;38(4):268-75. doi: 10.1111/j.1365-2362.2008.01931.x.

PMID:
18339007
25.

Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors.

Kundel Y, Yellin A, Popovtzer A, Pfeffer R, Symon Z, Simansky DA, Oberman B, Sadezki S, Brenner B, Catane R, Levitt ML.

Am J Clin Oncol. 2007 Aug;30(4):389-94.

PMID:
17762439
26.

A phase II study of oral UFT and leucovorin concurrently with pelvic irradiation as neoadjuvant chemoradiation for rectal cancer.

Kundel Y, Brenner B, Symon Z, Oberman B, Sadezki S, Koller M, Catane R, Pfeffer R.

Anticancer Res. 2007 Jul-Aug;27(4C):2877-80.

27.

[Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].

Raccah E, Merimsky O, Kuten A, Apter S, Catane R.

Harefuah. 2007 May;146(5):329-34, 408. Hebrew.

PMID:
17674545
28.

High incidence of fistula formation during bevacizumab treatment in rectal cancer patients.

Wolf I, Urban D, Pfeffer R, Catane R, Aderka D.

Acta Oncol. 2007;46(4):550-3. No abstract available.

PMID:
17497324
29.

[Body weight, nutritional factors and physical activity--their influence on prognosis after breast cancer diagnosis].

Weitzen R, Tichler T, Kaufman B, Catane R, Shpatz Y.

Harefuah. 2006 Nov;145(11):820-5, 861. Review. Hebrew.

PMID:
17183955
30.

MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases--preliminary clinical experience.

Catane R, Beck A, Inbar Y, Rabin T, Shabshin N, Hengst S, Pfeffer RM, Hanannel A, Dogadkin O, Liberman B, Kopelman D.

Ann Oncol. 2007 Jan;18(1):163-7. Epub 2006 Oct 9.

PMID:
17030549
31.

Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models.

Symon Z, Kundel Y, Sadetzki S, Oberman B, Ramon J, Laufer M, Catane R, Pfeffer MR.

Am J Clin Oncol. 2006 Oct;29(5):446-50.

PMID:
17023777
32.

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.

Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M.

Oral Oncol. 2007 Jan;43(1):33-6. Epub 2006 Jun 6.

PMID:
16757202
33.

Problems of opioid availability and accessibility across Europe: ESMO tackles the regulatory causes of intolerable and needless suffering.

Cherny NI, Catane R, Kosmidis PA.

Ann Oncol. 2006 Jun;17(6):885-7. Epub 2006 Apr 20. No abstract available.

PMID:
16627549
34.

Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.

Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B, Schachter J.

Isr Med Assoc J. 2006 Mar;8(3):164-8.

35.

Association between diabetes mellitus and adverse characteristics of breast cancer at presentation.

Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, Catane R, Kaufman B.

Eur J Cancer. 2006 May;42(8):1077-82. Epub 2006 Mar 29.

PMID:
16574404
36.

Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.

Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3770-4. Epub 2006 Feb 28.

37.

Breast cancer and scleroderma.

Scope A, Sadetzki S, Sidi Y, Barzilai A, Trau H, Kaufman B, Catane R, Ehrenfeld M.

Skinmed. 2006 Jan-Feb;5(1):18-24.

PMID:
16522978
38.

[Medical students and cancer].

Kaufman B, Catane R.

Harefuah. 2006 Jan;145(1):38. Hebrew. No abstract available.

PMID:
16450724
39.

Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients.

Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, Oberman B, Catane R, Kaufman B, Shimon I.

Cancer. 2006 Feb 15;106(4):966-73.

40.

[Update on the treatment of common gastrointestinal malignancies].

Wolf I, Catane R, Symon Z, Papa MZ, Fider HH.

Harefuah. 2005 Jan;144(1):39-44, 70. Review. Hebrew.

PMID:
15719821
41.

Diabetes mellitus and breast cancer.

Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B.

Lancet Oncol. 2005 Feb;6(2):103-11. Review.

PMID:
15683819
42.

A phase I study of oral UFT given concomitantly with standard preoperative radiotherapy for rectal cancer.

Pfeffer MR, Kundel Y, Zehavi M, Catane R, Koller M, Zmora O, Elkayam R, Symon Z.

Isr Med Assoc J. 2004 Oct;6(10):595-8.

43.

Salvage prostatic fossa radiation therapy for biochemical failure after radical prostatectomy: the Sheba experience.

Kundel Y, Pfeffer R, Lauffer M, Ramon J, Catane R, Symon Z.

Isr Med Assoc J. 2004 Jun;6(6):329-31.

PMID:
15214457
44.

Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor.

Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, Cherny NI.

Anticancer Drugs. 2004 Jul;15(6):599-602.

PMID:
15205603
45.

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group.

Ann Oncol. 2004 Mar;15(3):440-9.

PMID:
14998846
46.
47.

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.

Köhne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ.

Br J Cancer. 2003 Sep 15;89(6):997-1001.

48.

ESMO takes a stand on supportive and palliative care.

Cherny NI, Catane R, Kosmidis P; ESMO Taskforce on Supportive and Palliative Care.

Ann Oncol. 2003 Sep;14(9):1335-7. No abstract available.

PMID:
12954570
49.

A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.

Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S, Chompret A, Avril MF, Shafir R, Peretz H, Bressac-de Paillerets B.

Eur J Hum Genet. 2003 Apr;11(4):288-96.

50.

CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.

Ron IG, Wigler N, Borovik R, Peretz T, Rizel S, Shani A, Brenner J, Farbstein H, Brenner HJ, Chaitchik S, Catane R, Inbar MJ.

Am J Clin Oncol. 2002 Oct;25(5):520-2.

PMID:
12393997

Supplemental Content

Loading ...
Support Center